Digistain Analysis
What is Digistain?
Digistain offers an AI-enabled tumor profiling test to evaluate breast cancer recurrence risk, facilitating personalized treatment decisions for patients post-surgery.
Employees
40
Founded
2019
Revenue
$2.3M
Investors
- Sofia Angels Ventures
Product Features & Capabilities
- tumour profiling technology, Digistain Prognostic Score, predicts 10-year risk of recurrence, personalized treatment plans, results in under 1 hour, lower costs, seamless integration with clinical workflows
Who are the founders of Digistain
HA
CP
Chris Phillips
Founder
Market Focus
Digistain primarily focuses on the healthcare industry, specifically in the field of oncology, with a particular emphasis on breast cancer treatment through tumor profiling technology.
Competitors Overview
Digistain operates in the tumor profiling market, specifically focusing on breast cancer risk assessment. Its main competitors include:
- Oncotype DX: This test analyzes the activity of 21 genes to predict the risk of breast cancer recurrence and the potential benefit of chemotherapy. It is wi
See something that needs updating? Suggest edits to this profile.